Publications by authors named "J B Burks"
Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression.
View Article and Find Full Text PDFArticle Synopsis
- Angioimmunoblastic T-cell lymphoma (AITL) arises from follicular helper T (Tfh) cells and is difficult to treat due to its resistance to current therapies.
- The progression of AITL involves a complex interaction between neoplastic Tfh cells and B-cells in the tumor microenvironment, similar to processes in germinal centers.
- Recurrent mutations like TET2 and DNMT3A in both Tfh and B-cells hint that their relationship could be a potential target for new treatments, highlighting important signaling mechanisms in AITL's pathobiology.
Article Synopsis
- * A multicenter analysis involved 269 patients, reporting a high success rate (100% effective distal penetration), a low complication rate (2.2%), and significant improvements in cSDH diameter and neurological function at 60-day follow-up.
- * The findings suggest that using MMA embolization with the n-BCA D5W push technique is a safe and viable option alongside or instead of traditional surgery, showing a reduction in recurrence
Unlabelled: Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney neoplasm; bone metastasis (BM) develops in 35% to 40% of metastatic patients and results in substantial morbidity and mortality, as well as medical costs. A key feature of ccRCC is the loss of function of the von Hippel-Lindau protein, which enhances angiogenesis via vascular endothelial growth factor release. Consequently, antiangiogenic tyrosine kinase inhibitors (TKI) emerged as a treatment for ccRCC.
View Article and Find Full Text PDFThe incidence of human papilloma virus-mediated oropharyngeal squamous cell carcinoma (OPSCC) has increased over the past 40 years, particularly among young individuals with a favorable prognosis; however, current therapy often leads to unfortunate side effects, such as dysphagia. Despite the emphasis on dysphagia in previous studies, there is an important research gap in understanding the correlation between neuronal changes and patient-reported and functional outcomes in patients with OPSCC. To address this issue, we examined pathologic tissue samples from patients with OPSCC using multiplex immunofluorescence staining and machine learning to correlate tumor-associated neuronal changes with prospectively collected patient-reported and functional outcomes.
View Article and Find Full Text PDF